Pub Date : 2023-12-09DOI: 10.18502/bccr.v14i2.14374
S. Alipour, Amirhossein Eskandari
Advanced glycation end products (AGEs) are mediators of chronic inflammation, which is recognized as an underlying process in carcinogenesis. The role of AGEs in cancers is the focus of recent studies. Breast cancer (BC) is the most common cancer in the world and the etiology is unknown, but some risk factors have been defined; including obesity and diabetes. Both of these disorders are linked to AGEs; thus, BC and AGEs might be associated. AGEs in the human body either derive from the glycation of proteins and lipids in the blood, or from the dietary AGEs (dAGE). AGEs are mainly associated with disease states or aging, including diabetes mellitus, cardiovascular and cerebrovascular disorders, Alzheimer, renal failure, arthritis, skin problems, viral infections, and osteoporosis. Some bioeffects of AGEs are consistent with the chain of events that occur during carcinogenesis. However, the studies about the role of AGEs in specific cancers are not conclusive, and some recent literature, especially clinical studies do not support the theory of the association between AGEs and cancers,. There does not exist a great deal of studies about the role of AGEs in BC, but the subject has been addressed recently. The present evidence is rather in favor of the association of AGEs and breast cancer; however, the direction and type of this association are unclear. In-vitro studies show that AGEs promote features of invasiveness in BC, but clinical studies show diverse findings. In this study, we present an overview of the core existing knowledge about AGEs and their relation with diseases; then provide a brief review of the results of studies that have investigated the association of AGEs and cancer, and then proceed to a concise discussion about studies on AGEs and BC.
{"title":"Advanced glycation end products and breast cancer: a review of the literature","authors":"S. Alipour, Amirhossein Eskandari","doi":"10.18502/bccr.v14i2.14374","DOIUrl":"https://doi.org/10.18502/bccr.v14i2.14374","url":null,"abstract":"Advanced glycation end products (AGEs) are mediators of chronic inflammation, which is recognized as an underlying process in carcinogenesis. The role of AGEs in cancers is the focus of recent studies. Breast cancer (BC) is the most common cancer in the world and the etiology is unknown, but some risk factors have been defined; including obesity and diabetes. Both of these disorders are linked to AGEs; thus, BC and AGEs might be associated. AGEs in the human body either derive from the glycation of proteins and lipids in the blood, or from the dietary AGEs (dAGE). AGEs are mainly associated with disease states or aging, including diabetes mellitus, cardiovascular and cerebrovascular disorders, Alzheimer, renal failure, arthritis, skin problems, viral infections, and osteoporosis. Some bioeffects of AGEs are consistent with the chain of events that occur during carcinogenesis. However, the studies about the role of AGEs in specific cancers are not conclusive, and some recent literature, especially clinical studies do not support the theory of the association between AGEs and cancers,. There does not exist a great deal of studies about the role of AGEs in BC, but the subject has been addressed recently. The present evidence is rather in favor of the association of AGEs and breast cancer; however, the direction and type of this association are unclear. In-vitro studies show that AGEs promote features of invasiveness in BC, but clinical studies show diverse findings. In this study, we present an overview of the core existing knowledge about AGEs and their relation with diseases; then provide a brief review of the results of studies that have investigated the association of AGEs and cancer, and then proceed to a concise discussion about studies on AGEs and BC.","PeriodicalId":280576,"journal":{"name":"Basic & Clinical Cancer Research","volume":"5 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138585495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-09DOI: 10.18502/bccr.v14i3.14352
Maryam Naseri, Amir Mohamad Hashem Asnaashari, S. Sorouri
Lung cancer is one of the most fatal types of cancer and paraneoplastic syndromes are commonly associated with lung cancer. Paraneoplastic Cushing can be associated with different types of tumors, especially small cell lung cancer (SCLC). The aim of this report was to describe the status of a patient presenting with progressive weakness, who did not have a previous medical history. Clinical examination revealed bilateral edema of the lower limbs. Lab results exhibited severe hypokalemia and metabolic alkalosis. physical examination showed elevated blood pressure. Imaging revealed a large mass with necrosis. Bronchoscopy was done and biopsy pathology showed SCLC. The patient underwent chemotherapy with cisplatin and etoposide. Following SCLC, the patient developed a type of paraneoplastic syndrome called Cushing syndrome. He experienced a severe decrease in saturation in the second session of chemotherapy and eventually died. With respect to the fact that most paraneoplastic syndromes are associated with poor response to treatment, high clinical suspicion is essential for the rapid diagnosis of these syndromes to improve outcomes.
{"title":"Cushing syndrome in a 55-year-old case of small-cell lung cancer","authors":"Maryam Naseri, Amir Mohamad Hashem Asnaashari, S. Sorouri","doi":"10.18502/bccr.v14i3.14352","DOIUrl":"https://doi.org/10.18502/bccr.v14i3.14352","url":null,"abstract":"Lung cancer is one of the most fatal types of cancer and paraneoplastic syndromes are commonly associated with lung cancer. Paraneoplastic Cushing can be associated with different types of tumors, especially small cell lung cancer (SCLC). The aim of this report was to describe the status of a patient presenting with progressive weakness, who did not have a previous medical history. Clinical examination revealed bilateral edema of the lower limbs. Lab results exhibited severe hypokalemia and metabolic alkalosis. physical examination showed elevated blood pressure. Imaging revealed a large mass with necrosis. Bronchoscopy was done and biopsy pathology showed SCLC. The patient underwent chemotherapy with cisplatin and etoposide. Following SCLC, the patient developed a type of paraneoplastic syndrome called Cushing syndrome. He experienced a severe decrease in saturation in the second session of chemotherapy and eventually died. With respect to the fact that most paraneoplastic syndromes are associated with poor response to treatment, high clinical suspicion is essential for the rapid diagnosis of these syndromes to improve outcomes.","PeriodicalId":280576,"journal":{"name":"Basic & Clinical Cancer Research","volume":"263 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138983186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: We aimed to investigate safety and efficacy of preoperative chemotherapy using EOX regime in patients with locally advanced gastric and GEJ cancer who were admitted at Imam-Khomeini Oncology clinic and Aram clinic. Method: We performed a mix-cohort study in 51 gastric cancer patients. In the beginning, we performed contrast thorax and abdominal CT scan or ECO cardiograph to determine cancer staging. After that, each patient received 3-weeks EOX regime in 6 cycle. After each three cycles follow-up CT scan was performed to assess any possible progression. Response to the treatment, Overall survival, and Progression-Free Survival were the main outcomes that we evaluated in the current study. We used Kaplan-Meier approach and Cox regression to address survival rate and its prognostic factors Results: Overall, 72.5% percent were male and mean age of study participants was 57.6. Complete response rate was observed in 11.1%, while 51.1% showed partial response. Median of overall survival and Progression-Free Survival was estimated 35.0 and 28.0 month, respectively. The 5-year overall survival was 74.2% and for PFS it was estimated at 57.7%. Conclusion: Preoperative chemotherapy using EOX regime could increase survival rate among patients with gastric and GEJ cancer.
{"title":"Survival of GEJ and gastric adenocarcinoma patients admitted at Imam Khomeini and Aram oncology clinic and treated with preoperative EOX chemotherapy","authors":"Ali Farahat, Amirhossein Emami, Seyed Reza Safaei Nodehi, Kamran Roudini, Farhad Shahi","doi":"10.18502/bccr.v14i2.14375","DOIUrl":"https://doi.org/10.18502/bccr.v14i2.14375","url":null,"abstract":"Objective: We aimed to investigate safety and efficacy of preoperative chemotherapy using EOX regime in patients with locally advanced gastric and GEJ cancer who were admitted at Imam-Khomeini Oncology clinic and Aram clinic. \u0000Method: We performed a mix-cohort study in 51 gastric cancer patients. In the beginning, we performed contrast thorax and abdominal CT scan or ECO cardiograph to determine cancer staging. After that, each patient received 3-weeks EOX regime in 6 cycle. After each three cycles follow-up CT scan was performed to assess any possible progression. Response to the treatment, Overall survival, and Progression-Free Survival were the main outcomes that we evaluated in the current study. We used Kaplan-Meier approach and Cox regression to address survival rate and its prognostic factors \u0000Results: Overall, 72.5% percent were male and mean age of study participants was 57.6. Complete response rate was observed in 11.1%, while 51.1% showed partial response. Median of overall survival and Progression-Free Survival was estimated 35.0 and 28.0 month, respectively. The 5-year overall survival was 74.2% and for PFS it was estimated at 57.7%. \u0000Conclusion: Preoperative chemotherapy using EOX regime could increase survival rate among patients with gastric and GEJ cancer.","PeriodicalId":280576,"journal":{"name":"Basic & Clinical Cancer Research","volume":"409 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138983107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-09DOI: 10.18502/bccr.v14i2.14377
Hossein Mehrani, S. Yasini, A. Muhammadnejad, Seyed Hamed Shirazi Beheshtiha
Background: Melanoma is the cause of death for 1.3% of all cancer patients in humans. The key role of the BRAF protein in the progression of human melanoma has been confirmed, and its prognostic significance has been revealed. Because canine cancer resembles human cancer in biological behavior and molecular abnormalities, BRAF protein may be expressed in canine melanoma, the same as human melanoma. Despite the investigation of the BRAF mutation in canine melanoma, the status of BRAF at the protein level in canine skin melanoma has not yet been examined. Methods: Thirty-two formalin-fixed, paraffin-embedded tissue samples of canine malignant cutaneous melanoma were randomly selected. After cutting into 3-μmthick sections, the samples were evaluated for BRAF protein expression by immunohistochemistry and using the anti-BRAF V600E (VE1) mouse monoclonal antibody Results: The BRAF status was assessed using the Allred scoring system. Among the 32 samples examined, 21 samples were negative, and 11 cases showed high BRAF protein expression. Conclusion: The detection of positive BRAF expression in 34.3% of canine cutaneous melanoma samples could be a step forward to improving treatment options, using dogs as an animal model in human melanoma clinical trials, and possibly identifying a new prognostic biomarker in canine melanoma.
{"title":"BRAF-V600E Protein Expression in Canine Malignant Cutaneous Melanoma, in Accordance with the Introduction of Biomarkers in Comparative Oncology Studies","authors":"Hossein Mehrani, S. Yasini, A. Muhammadnejad, Seyed Hamed Shirazi Beheshtiha","doi":"10.18502/bccr.v14i2.14377","DOIUrl":"https://doi.org/10.18502/bccr.v14i2.14377","url":null,"abstract":"Background: Melanoma is the cause of death for 1.3% of all cancer patients in humans. The key role of the BRAF protein in the progression of human melanoma has been confirmed, and its prognostic significance has been revealed. Because canine cancer resembles human cancer in biological behavior and molecular abnormalities, BRAF protein may be expressed in canine melanoma, the same as human melanoma. Despite the investigation of the BRAF mutation in canine melanoma, the status of BRAF at the protein level in canine skin melanoma has not yet been examined. \u0000Methods: Thirty-two formalin-fixed, paraffin-embedded tissue samples of canine malignant cutaneous melanoma were randomly selected. After cutting into 3-μmthick sections, the samples were evaluated for BRAF protein expression by immunohistochemistry and using the anti-BRAF V600E (VE1) mouse monoclonal antibody \u0000Results: The BRAF status was assessed using the Allred scoring system. Among the 32 samples examined, 21 samples were negative, and 11 cases showed high BRAF protein expression. \u0000Conclusion: The detection of positive BRAF expression in 34.3% of canine cutaneous melanoma samples could be a step forward to improving treatment options, using dogs as an animal model in human melanoma clinical trials, and possibly identifying a new prognostic biomarker in canine melanoma.","PeriodicalId":280576,"journal":{"name":"Basic & Clinical Cancer Research","volume":"21 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138585056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-09DOI: 10.18502/bccr.v14i3.14354
M. Moghimi, Mehran Jafari, K. Ansari
Objective: The aim this study was How to report pathological indicators of gastric malignancies in a hospital in Iran, a developing country. Method: This cross-sectional study was conducted on 174 patients. Study variables including age and sex, type of biopsy, extent of gastric tissue involvement, exact anatomical location, tumor size, histological grading, invasion of surrounding tissues and lymph node metastasis were extracted from patients’ records. Data were analyzed using SPSS 22 software. Frequency and percentage were reported using descriptive statistics. Graphs were drawn using Excel 2010. Results: 174 patients were studied in this study; that 63.8% of the patients were female (n= 111). The prevalent of reports were related to the histology of adenocarcinoma (n = 136, p = 78.20), tumor size (n = 89, p = 51.15), anatomical exact location (n = 90, p = 51.70), respectively. Among the 90 patients for whom the exact anatomical location was reported, the most reports were related to the antrum (n = 38, p = 42.23). The highest prevalence of histological type of adenocarcinoma was related to Poorly differentiated (n = 57, p = 41.94). Conclusion: The findings of this study showed that the way of reporting pathological indicators in gastric malignancies in the studied cases was somewhat appropriate.
目的:探讨发展中国家伊朗某医院胃恶性肿瘤病理指标的报告方法。方法:对174例患者进行横断面研究。研究变量包括患者的年龄和性别、活检类型、胃组织受累程度、确切解剖位置、肿瘤大小、组织学分级、周围组织的浸润和淋巴结转移。数据分析采用SPSS 22软件。使用描述性统计报告频率和百分比。图表使用Excel 2010绘制。结果:本研究纳入174例患者;其中女性占63.8% (n= 111)。报告的发生率分别与腺癌的组织学(n = 136, p = 78.20)、肿瘤大小(n = 89, p = 51.15)、解剖确切位置(n = 90, p = 51.70)有关。在90例报告确切解剖位置的患者中，与上颌窦有关的报道最多(n = 38, p = 42.23)。腺癌的组织学类型与低分化相关的发生率最高(n = 57, p = 41.94)。结论:本研究结果表明，所研究的胃恶性肿瘤病理指标的报告方式是适当的。
{"title":"How to report pathological indicators of gastric malignancies in a hospital in Iran, a developing country","authors":"M. Moghimi, Mehran Jafari, K. Ansari","doi":"10.18502/bccr.v14i3.14354","DOIUrl":"https://doi.org/10.18502/bccr.v14i3.14354","url":null,"abstract":"Objective: The aim this study was How to report pathological indicators of gastric malignancies in a hospital in Iran, a developing country. \u0000Method: This cross-sectional study was conducted on 174 patients. Study variables including age and sex, type of biopsy, extent of gastric tissue involvement, exact anatomical location, tumor size, histological grading, invasion of surrounding tissues and lymph node metastasis were extracted from patients’ records. Data were analyzed using SPSS 22 software. Frequency and percentage were reported using descriptive statistics. Graphs were drawn using Excel 2010. \u0000Results: 174 patients were studied in this study; that 63.8% of the patients were female (n= 111). The prevalent of reports were related to the histology of adenocarcinoma (n = 136, p = 78.20), tumor size (n = 89, p = 51.15), anatomical exact location (n = 90, p = 51.70), respectively. Among the 90 patients for whom the exact anatomical location was reported, the most reports were related to the antrum (n = 38, p = 42.23). The highest prevalence of histological type of adenocarcinoma was related to Poorly differentiated (n = 57, p = 41.94). \u0000Conclusion: The findings of this study showed that the way of reporting pathological indicators in gastric malignancies in the studied cases was somewhat appropriate.","PeriodicalId":280576,"journal":{"name":"Basic & Clinical Cancer Research","volume":"24 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138585274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-09DOI: 10.18502/bccr.v14i2.14376
Kamran Roudini, M. Mirzania, Seyyed Amirhossein Emami, Seyyed Reza Safayi, Ehsan Kamali Yazdi, Nasim Zarifi, Masoud Mortezazadeh, Shima Rafiee, Abbas Mofidi, M. Kashani, Ensieh sadat Mansouri, Mohammad Rasekhi Siahkal mahalleh, Ahmad Khajeh Mehrizi
Background: This study evaluated the effect of adjuvant chemotherapy and hormone therapy on overall survival and disease-free survival in patients with breast cancer with hormone receptor-positive, HER2-negative tumors without lymph node involvement. Methods: Breast cancer patients with hormone receptor-positive, HER2-negative, and no lymph node involvement were included in this retrospective cohort study. Patient records were used to collect data on sex, age, time of disease onset, tumor subtype, tumor size, grade, lymphovascular and perineural involvement, ki67, and treatment protocols. Patients were divided into 2 groups: Patients who received both adjuvant chemotherapy and hormonal therapy and patients who received hormonal therapy only. Disease-free survival index (DFS) and overall survival index (OS) were evaluated. Results: Sixty-seven female patients were enrolled in this study. Of them, 68.2% received both adjuvant chemotherapy and hormonal therapy and 31.6% received hormonal therapy only. During follow-up, recurrences occurred in 8 patients. The 3-year and 5-year DFS were 93.4% and 90%, respectively. The 3-year and 5-year DFS was 94% and 92%, respectively, in patients who received both adjuvant chemotherapy and hormonal therapy, and 91% and 85%, respectively, in patients who received hormonal therapy. None of the factors studied affected the 3-year and 5-year DFS. The 3-year and 5-year DFS OS were 98.6% and 96.9%, respectively Conclusion: Adjuvant chemotherapy in patients with breast cancer with hormone receptor-positive, HER2-negative, and no lymph node involvement compared with similar patients receiving hormone therapy alone had no significant difference in disease-free survival index and overall survival index.
{"title":"Evaluation of overall survival and disease-free survival of adjuvant chemotherapy and hormone therapy in patients with breast cancer","authors":"Kamran Roudini, M. Mirzania, Seyyed Amirhossein Emami, Seyyed Reza Safayi, Ehsan Kamali Yazdi, Nasim Zarifi, Masoud Mortezazadeh, Shima Rafiee, Abbas Mofidi, M. Kashani, Ensieh sadat Mansouri, Mohammad Rasekhi Siahkal mahalleh, Ahmad Khajeh Mehrizi","doi":"10.18502/bccr.v14i2.14376","DOIUrl":"https://doi.org/10.18502/bccr.v14i2.14376","url":null,"abstract":"Background: This study evaluated the effect of adjuvant chemotherapy and hormone therapy on overall survival and disease-free survival in patients with breast cancer with hormone receptor-positive, HER2-negative tumors without lymph node involvement. \u0000Methods: Breast cancer patients with hormone receptor-positive, HER2-negative, and no lymph node involvement were included in this retrospective cohort study. Patient records were used to collect data on sex, age, time of disease onset, tumor subtype, tumor size, grade, lymphovascular and perineural involvement, ki67, and treatment protocols. Patients were divided into 2 groups: Patients who received both adjuvant chemotherapy and hormonal therapy and patients who received hormonal therapy only. Disease-free survival index (DFS) and overall survival index (OS) were evaluated. \u0000Results: Sixty-seven female patients were enrolled in this study. Of them, 68.2% received both adjuvant chemotherapy and hormonal therapy and 31.6% received hormonal therapy only. During follow-up, recurrences occurred in 8 patients. The 3-year and 5-year DFS were 93.4% and 90%, respectively. The 3-year and 5-year DFS was 94% and 92%, respectively, in patients who received both adjuvant chemotherapy and hormonal therapy, and 91% and 85%, respectively, in patients who received hormonal therapy. None of the factors studied affected the 3-year and 5-year DFS. The 3-year and 5-year DFS OS were 98.6% and 96.9%, respectively \u0000Conclusion: Adjuvant chemotherapy in patients with breast cancer with hormone receptor-positive, HER2-negative, and no lymph node involvement compared with similar patients receiving hormone therapy alone had no significant difference in disease-free survival index and overall survival index.","PeriodicalId":280576,"journal":{"name":"Basic & Clinical Cancer Research","volume":"16 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138585566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-08DOI: 10.18502/bccr.v14i3.14351
Seyed Ali Asghar Razavi, A. M. Chelak, A. Riahi
Introduction: This study was aimed to identify the sanitary and health-oriented and information needs of Afghan immigrant women with breast cancer who are being treated and coping with their disease in health centers and hospitals in Iran. Method: The present study is a survey and applied in terms of purpose. The study population consisted of 72 Afghan immigrant female patients with breast cancer. A researcher-made questionnaire was used to collect information divided into 6 sections and had 65 questions. Kruskal-Wallis,Mann-Whitney U tests, and SPSS statistical software version 20 were used to analyze the data. Findings: The results showed no significant difference between the health information needs of immigrants based on age, marital status, literacy rate, occupation, treatment stage, manner and place of residence, and other demographic characteristics. “Achieving a healthy life” has been identified as the most critical information need (with a mean of 4.14), and “lack of familiarity with traditional sources related to sanitary and health” has been identified as the most crucial barrier (with a mean of 3.99) in accessing sanitary and health information. Conclusion: Paying attention to the information needs of cancer patients, especially immigrants and refugees with cultural differences and many social gaps with the host community (Iran), seems inevitable. As a result of being aware of the health information needs of these people in different stages of treatment and providing appropriate information by health professionals, informants, doctors, nurses, and medical staff, the situation will provide for better and more effective treatment of these patients in addition to reducing mental anxiety and psychological security in patients.
{"title":"Necessary Information of Afghan Immigrant Women with Breast Cancer in Iran in the Field of Health and Sanitary and the Way to Access it","authors":"Seyed Ali Asghar Razavi, A. M. Chelak, A. Riahi","doi":"10.18502/bccr.v14i3.14351","DOIUrl":"https://doi.org/10.18502/bccr.v14i3.14351","url":null,"abstract":"Introduction: This study was aimed to identify the sanitary and health-oriented and information needs of Afghan immigrant women with breast cancer who are being treated and coping with their disease in health centers and hospitals in Iran. \u0000Method: The present study is a survey and applied in terms of purpose. The study population consisted of 72 Afghan immigrant female patients with breast cancer. A researcher-made questionnaire was used to collect information divided into 6 sections and had 65 questions. Kruskal-Wallis,Mann-Whitney U tests, and SPSS statistical software version 20 were used to analyze the data. \u0000Findings: The results showed no significant difference between the health information needs of immigrants based on age, marital status, literacy rate, occupation, treatment stage, manner and place of residence, and other demographic characteristics. “Achieving a healthy life” has been identified as the most critical information need (with a mean of 4.14), and “lack of familiarity with traditional sources related to sanitary and health” has been identified as the most crucial barrier (with a mean of 3.99) in accessing sanitary and health information. \u0000Conclusion: Paying attention to the information needs of cancer patients, especially immigrants and refugees with cultural differences and many social gaps with the host community (Iran), seems inevitable. As a result of being aware of the health information needs of these people in different stages of treatment and providing appropriate information by health professionals, informants, doctors, nurses, and medical staff, the situation will provide for better and more effective treatment of these patients in addition to reducing mental anxiety and psychological security in patients.","PeriodicalId":280576,"journal":{"name":"Basic & Clinical Cancer Research","volume":"417 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139010939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-20DOI: 10.18502/bccr.v13i3.11402
Elham Bahrami Salehloo, Najmeh Mozdoori, M. J. Dehghan Esmatabadi, Samira Hajigholami, A. Bozorgmehr
Progress in cancer stem cells (CSCs) has opened up a new window to develop better cancer treatment methods. Several preclinical and clinical trial studies use CSCs targeting via surface markers method and inhibiting stem cell pathway to eradicate cancer. Investigations disclose that CSCs are more resistant to chemo- and radiotherapy than non-CSCs. If CSCs are destroyed with treatment, cancer cells will be deleted. This feature is mainly related to their surface biomarkers and thus, detection and Isolation of CSCs are so critical. This study introduced the most important cell surface markers of CSCs such as CD133, CD44, CD24, and CD90 and evaluated these biomarkers. Today, more than 60 ongoing trials have been evaluated, few of which are used in clinical trials to determine if a new drug is effective. Then, we discuss the challenges of several therapies.
{"title":"Cancer Stem Cell Biomarkers: Critical Roles, Challenges, Clinical Application, and Perspectives in Cancer Therapy","authors":"Elham Bahrami Salehloo, Najmeh Mozdoori, M. J. Dehghan Esmatabadi, Samira Hajigholami, A. Bozorgmehr","doi":"10.18502/bccr.v13i3.11402","DOIUrl":"https://doi.org/10.18502/bccr.v13i3.11402","url":null,"abstract":"Progress in cancer stem cells (CSCs) has opened up a new window to develop better cancer treatment methods. Several preclinical and clinical trial studies use CSCs targeting via surface markers method and inhibiting stem cell pathway to eradicate cancer. Investigations disclose that CSCs are more resistant to chemo- and radiotherapy than non-CSCs. If CSCs are destroyed with treatment, cancer cells will be deleted. This feature is mainly related to their surface biomarkers and thus, detection and Isolation of CSCs are so critical. This study introduced the most important cell surface markers of CSCs such as CD133, CD44, CD24, and CD90 and evaluated these biomarkers. Today, more than 60 ongoing trials have been evaluated, few of which are used in clinical trials to determine if a new drug is effective. Then, we discuss the challenges of several therapies.","PeriodicalId":280576,"journal":{"name":"Basic & Clinical Cancer Research","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117054519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-20DOI: 10.18502/bccr.v13i3.11406
A. Alizadehasl, Niloufar Akbari Parsa, F. Noohi, Reza Golpira, Amir Abdi, A. Emami, A. Moosavi, G. Janbabaei
Advances in cancer treatment have resulted in a growing number of cancer survivors. However, powerful treatments such as chemotherapy, radiation treatments, and some cancer drugs are not without risks, including the potential for serious, long-term damage to the heart. Cardiology and oncology specialists often collaborate to mitigate these risks when treating cancer patients. This joining is known as cardio-oncology. The main goals of cardio-oncology are to screen for and actively manage modifiable cardiovascular risk factors and diseases in cancer patients. Cardio-oncology plays an increasingly active role at every stage of cancer therapy, including baseline risk assessment pretreatment, surveillance and prevention during treatment, response to acute complications, and assessment of survivors’ post-cardiotoxic treatments. Cancer treatment has been optimized through new treatment strategies. The first cardio-oncology clinic in Iran was instituted about 4 years ago (2017) at Shaheed Rajaei Cardiovascular Medical and Research Center in Tehran, which is the first cardio-oncology clinic in the Middle East. It provides care for cancer patients with a history of cardiovascular disease or risk for cardiotoxicity during cancer therapy. Also, all patients are enrolled in the multicenter cardio-oncology Toxicity Registry research database, and 13 other hospitals from different centers in the whole country are involved in the registry. The establishment of the cardio-oncology clinic with a focus on the patient registry is discussed in this article.
{"title":"Cardio-Oncology in Iran: Cardio-toxicity Registry","authors":"A. Alizadehasl, Niloufar Akbari Parsa, F. Noohi, Reza Golpira, Amir Abdi, A. Emami, A. Moosavi, G. Janbabaei","doi":"10.18502/bccr.v13i3.11406","DOIUrl":"https://doi.org/10.18502/bccr.v13i3.11406","url":null,"abstract":"Advances in cancer treatment have resulted in a growing number of cancer survivors. However, powerful treatments such as chemotherapy, radiation treatments, and some cancer drugs are not without risks, including the potential for serious, long-term damage to the heart. Cardiology and oncology specialists often collaborate to mitigate these risks when treating cancer patients. This joining is known as cardio-oncology. The main goals of cardio-oncology are to screen for and actively manage modifiable cardiovascular risk factors and diseases in cancer patients. Cardio-oncology plays an increasingly active role at every stage of cancer therapy, including baseline risk assessment pretreatment, surveillance and prevention during treatment, response to acute complications, and assessment of survivors’ post-cardiotoxic treatments. Cancer treatment has been optimized through new treatment strategies. The first cardio-oncology clinic in Iran was instituted about 4 years ago (2017) at Shaheed Rajaei Cardiovascular Medical and Research Center in Tehran, which is the first cardio-oncology clinic in the Middle East. It provides care for cancer patients with a history of cardiovascular disease or risk for cardiotoxicity during cancer therapy. Also, all patients are enrolled in the multicenter cardio-oncology Toxicity Registry research database, and 13 other hospitals from different centers in the whole country are involved in the registry. The establishment of the cardio-oncology clinic with a focus on the patient registry is discussed in this article.","PeriodicalId":280576,"journal":{"name":"Basic & Clinical Cancer Research","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128583387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-20DOI: 10.18502/bccr.v13i3.11404
M. Mobaraki, S. Angaji, E. Nazemalhosseini-Mojarad, S. Arbabian, H. Asadzadeh Aghdaei
Background: Recently, it has been shown that, piwi-interacting RNAs (piRNAs) as a new class of non-coding RNAs (ncRNAs), play crucial roles in germline development and carcinogenesis. Despite this, the study on the effects of piRNAs polymorphism (piR-SNP) on colorectal cancer (CRC) risk is scarce. We evaluate the impact of rs11776042 in piRNA 015551 on CRC initiation and development in the Iranian population for the first time. Methods: The association of novel polymorphisms rs11776042 in piRNA 015551 gene with CRC risk using a case-control study on the Iranian population was estimated. In this project 284 CRC patients and 389 non-cancerous controls were evaluated by TETRA primer-Amplification refractory mutation system polymerase chain reaction (TP-ARMS- PCR assay). Results: The genotypes frequency was 27%, 68% and 0.05% for C/C, C/T and T/T in controls and 31%, 65% and 0.04% in CRC patients respectively. The frequency of the C allele was 63% in patients versus 61% in controls and, T allele frequency was 37% in patients versus 39% in controls. Conclusion: No significant difference was found in genotype and allele frequencies between the cases and controls for rs11776042 polymorphism in piRNA 015551 in our population.
{"title":"The Evaluation Of rs11776042 Polymorphism Effect On Colorectal Cancer Risk In The Iranian Population: A Case-Control Study","authors":"M. Mobaraki, S. Angaji, E. Nazemalhosseini-Mojarad, S. Arbabian, H. Asadzadeh Aghdaei","doi":"10.18502/bccr.v13i3.11404","DOIUrl":"https://doi.org/10.18502/bccr.v13i3.11404","url":null,"abstract":"Background: Recently, it has been shown that, piwi-interacting RNAs (piRNAs) as a new class of non-coding RNAs (ncRNAs), play crucial roles in germline development and carcinogenesis. Despite this, the study on the effects of piRNAs polymorphism (piR-SNP) on colorectal cancer (CRC) risk is scarce. We evaluate the impact of rs11776042 in piRNA 015551 on CRC initiation and development in the Iranian population for the first time. \u0000Methods: The association of novel polymorphisms rs11776042 in piRNA 015551 gene with CRC risk using a case-control study on the Iranian population was estimated. In this project 284 CRC patients and 389 non-cancerous controls were evaluated by TETRA primer-Amplification refractory mutation system polymerase chain reaction (TP-ARMS- PCR assay). \u0000Results: The genotypes frequency was 27%, 68% and 0.05% for C/C, C/T and T/T in controls and 31%, 65% and 0.04% in CRC patients respectively. The frequency of the C allele was 63% in patients versus 61% in controls and, T allele frequency was 37% in patients versus 39% in controls. \u0000Conclusion: No significant difference was found in genotype and allele frequencies between the cases and controls for rs11776042 polymorphism in piRNA 015551 in our population.","PeriodicalId":280576,"journal":{"name":"Basic & Clinical Cancer Research","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121283639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：